SCYNEXIS Announces Exclusive License Agreement With GSK for Brexafemme

Palo Alto – April 4, 2023 – Cooley advised SCYNEXIS on its exclusive license agreement with GSK for Brexafemme. Lawyers Marya Postner, Carly Robinson, Bin Wang, Barbara Borden, Rebecca Givner-Forbes, Matt Hemington and Brett White led the Cooley team.

The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp – a US Food and Drug Administration-approved antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC that it being sold as Brexafemme – and to develop it for additional indications, including the treatment of invasive candidiasis (IC), a life-threatening fungal infection. Under the terms of the agreement, SCYNEXIS will receive an upfront payment of $90 million from GSK, with additional potential milestone-based payments totaling $503 million. If specific development, regulatory and commercial milestones for the IC indication are completed, GSK will pay up to $245.5 million, with a further $15 million upon successful FDA approval of an additional indication. GSK also will pay up to $242.5 million in sales-related milestone payments if certain commercial performance metrics are achieved and mid-single digit to mid-teen digit tiered royalties on the net sale totals across all indications, with the top royalty tier based on achieving more than $1 billion in annual net sales.

SCYNEXIS is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists have been developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in community and hospital settings.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.